Sionna Therapeutics to Engage Investors in December Conferences
Sionna Therapeutics, Inc. (NASDAQ: SION), a pioneering biopharmaceutical company, has made significant strides towards enhancing treatments for cystic fibrosis (CF). The company focuses on creating innovative therapies that normalize CFTR protein function, which plays a vital role in managing this challenging condition.
Upcoming Conferences
The management team from Sionna Therapeutics is scheduled to participate in several prominent investor events this December, specifically:
8th Annual Evercore Healthcare Conference
This event is set for December 3, where Sionna will present its advancements at 12:30 p.m. ET.
Citi 2025 Global Healthcare Conference
The following day, on December 4, Sionna will participate in discussions starting at 9:45 a.m. ET. These fireside chats will provide insights into the company's progress and future directions in CF treatment.
Accessing Live Presentations
For those interested in following these developments, live webcasts of Sionna's presentations will be accessible on the company's website under the 'Events' section. After the events, replays will also be available so that stakeholders can catch up on the discussions.
About Sionna Therapeutics
Founded with a clear mission, Sionna Therapeutics is dedicated to transforming how cystic fibrosis is treated. The company aims to develop medications that stabilize the CFTR protein's function, crucial for individuals living with CF. Sionna's dedication stems from over a decade of research focused on the CFTR's nucleotide binding domain 1 (NBD1). By addressing the genetic mutation F508del, which is prevalent among CF patients, Sionna aspires to enhance clinical outcomes significantly.
Innovative Drug Development
Sionna's pipeline currently includes a variety of small molecules designed to address the defects caused by the F508del mutation. Complementarily, the company is advancing CFTR modulators that synergize with its NBD1 stabilizers to ensure optimal CFTR function, which can lead to improved quality of life for patients.
Investor Relations Strategy
To remain transparent and compliant with regulatory requirements, Sionna Therapeutics will utilize its Investor Relations website for disclosing material nonpublic information. This approach provides investors a reliable channel for following the latest updates, press releases, SEC filings, and more.
Contact Information for Media and Investors
Adam Daley is the media contact at CG Life, available at 212.253.8881. Investors seeking additional information can reach Juliet Labadorf via email, at ir@sionnatx.com. This direct line of communication ensures that all stakeholders have access to important company developments.
Frequently Asked Questions
What is Sionna Therapeutics focusing on in cystic fibrosis treatment?
Sionna focuses on developing novel medicines to improve the function of the CFTR protein, which is vital for effective cystic fibrosis management.
When are Sionna's upcoming investor conferences?
Sionna will participate in the Evercore Healthcare Conference on December 3 and the Citi Global Healthcare Conference on December 4.
How can I watch Sionna's presentations?
Live webcasts of the presentations will be available on Sionna's Investor Relations website under the 'Events' section.
What is the aim of Sionna's drug development?
Sionna aims to create treatments that correct defects in the CFTR protein due to genetic mutations, enhancing the lives of cystic fibrosis patients.
Who can I contact for more information about Sionna?
For media inquiries, contact Adam Daley. For investor relations, reach out to Juliet Labadorf via email at ir@sionnatx.com.
